Sanofi’s Dupixent wins U.S. approval for bigger use

Author of the article: Sanofi on Friday won expanded U.S. approval for its best-selling Dupixent injection to treat an allergic inflammation of the esophagus, the Food and Drug Administration said. There are more than 160,000 patients in the United States living with eosinophilic esophagitis, according to Sanofi. The chronic condition typically requires repeated treatments such…
Sanofi’s Dupixent wins U.S. approval for bigger use

Author of the article:

Sanofi on Friday won expanded U.S. approval for its best-selling Dupixent injection to treat an allergic inflammation of the esophagus, the Food and Drug Administration said.

There are more than 160,000 patients in the United States living with eosinophilic esophagitis, according to Sanofi.

The chronic condition typically requires repeated treatments such as corticosterioids and diet change to ease the symptoms and Dupixent is the first treatment that targets the underlying cause.

Anti-inflammation drug Dupixent, jointly developed with Regeneron, is already approved for a range of other uses including atopic dermatitis, also known as eczema, and severe asthma.

Sanofi said in March it expected peak annual sales of more than 13 billion euros ($13.77 billion) for the drug, up from a previous target of over 10 billion euros.

That excluded the potential use in COPD, sometimes called smoker’s lung, where trial results are expected next year.

Dupixent, with 2021 sales of 5.25 billion euros, accounted for 13.9% of group revenue, by far Sanofi’s best-selling product.

Sanofi’s first-quarter adjusted earnings gained 16.2% on sales growth of the blockbuster drug and a rebound in demand for prescription-free drugs.

First-quarter revenue from Dupixent jumped over 45% to 1.61 billion euros, beating an analyst consensus, on prescriptions in dermatitis, asthma and certain nasal infections.

(Reporting by Ludwig Burger; Additional reporting by Eva Mathews; Editing by Maju Samuel)

Financial Post Top Stories

Sign up to receive the daily top stories from the Financial Post, a division of Postmedia Network Inc.

By clicking on the sign up button you consent to receive the above newsletter from Postmedia Network Inc. You may unsubscribe any time by clicking on the unsubscribe link at the bottom of our emails. Postmedia Network Inc. | 365 Bloor Street East, Toronto, Ontario, M4W 3L4 | 416-383-2300

Read More

Total
0
Shares
Leave a Reply

Your email address will not be published.

Related Posts
Imran Khan, cricket star turned Pakistan premier, is ousted
Read More

Imran Khan, cricket star turned Pakistan premier, is ousted

Author of the article: ISLAMABAD, April 10 – Imran Khan was ousted as Pakistan’s prime minister on Sunday after a no-confidence vote in parliament, bringing to a premature end a tenure marked by a deteriorating economy and signs that he had lost the trust of the powerful military. Defections from his coalition reflected growing disillusionment…
Olympics-Team Taiwan says it will be at Beijing Games opening ceremony
Read More

Olympics-Team Taiwan says it will be at Beijing Games opening ceremony

Author of the article: TAIPEI — Taiwan’s team for the Beijing Winter Olympics will be at the opening and closing ceremonies after being told by the International Olympic Committee it was required to participate. Chinese-claimed Taiwan has feared Beijing could “downgrade” Taiwan’s status by putting its athletes alongside those from Chinese-run Hong Kong at the…
BOJ to Review Outlook on Price Increases as Costs Rise: Yomiuri
Read More

BOJ to Review Outlook on Price Increases as Costs Rise: Yomiuri

Author of the article: Bloomberg News Takashi Mochizuki (Bloomberg) — The Bank of Japan may increase its forecast for inflation to reflect higher material costs when the board meets later this month, the Yomiuri newspaper reported, without saying where it got the information. The central bank’s outlook for price trends for the fiscal 2022, currently…
Washington subway to delay return of many railcars
Read More

Washington subway to delay return of many railcars

Author of the article: The Washington subway system said on Thursday that it plans to delay the return of trains like the one that derailed in October by another 90 days. Metro, the D.C.-area subway system, said it will not resume efforts to return 7000-series trains into passenger service to allow “engineering and mechanical experts…